ATE459877T1 - Diagnostikum für die frühe phase von morbus alzheimer - Google Patents

Diagnostikum für die frühe phase von morbus alzheimer

Info

Publication number
ATE459877T1
ATE459877T1 AT02804772T AT02804772T ATE459877T1 AT E459877 T1 ATE459877 T1 AT E459877T1 AT 02804772 T AT02804772 T AT 02804772T AT 02804772 T AT02804772 T AT 02804772T AT E459877 T1 ATE459877 T1 AT E459877T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
diagnostic
early phase
sulfatides
Prior art date
Application number
AT02804772T
Other languages
English (en)
Inventor
Xianlin Han
David Holtzman
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE459877T1 publication Critical patent/ATE459877T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02804772T 2001-12-10 2002-12-10 Diagnostikum für die frühe phase von morbus alzheimer ATE459877T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33918801P 2001-12-10 2001-12-10
PCT/US2002/039567 WO2003050528A1 (en) 2001-12-10 2002-12-10 Diagnostic for early stage alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE459877T1 true ATE459877T1 (de) 2010-03-15

Family

ID=23327889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804772T ATE459877T1 (de) 2001-12-10 2002-12-10 Diagnostikum für die frühe phase von morbus alzheimer

Country Status (7)

Country Link
US (1) US7015044B2 (de)
EP (1) EP1461611B1 (de)
AT (1) ATE459877T1 (de)
AU (1) AU2002366555A1 (de)
CA (1) CA2469486A1 (de)
DE (1) DE60235576D1 (de)
WO (1) WO2003050528A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108051A2 (en) * 2005-04-05 2006-10-12 Neurodx, Llc Compositions and methods relating to alzheimer's disease
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
FI20115576A0 (fi) 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy Menetelmä Alzheimerin taudin diagnoimiseksi
BR112015013498A2 (pt) * 2012-12-11 2017-07-11 Centogene Ag método para o diagnóstico de leucodistrofia metacromática
CN112834653B (zh) * 2021-04-09 2023-02-28 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f3及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197833B1 (en) * 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
EP1150695B1 (de) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
US6465195B2 (en) 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss

Also Published As

Publication number Publication date
EP1461611A4 (de) 2005-01-26
CA2469486A1 (en) 2003-06-19
EP1461611A1 (de) 2004-09-29
AU2002366555A1 (en) 2003-06-23
EP1461611B1 (de) 2010-03-03
WO2003050528A1 (en) 2003-06-19
US7015044B2 (en) 2006-03-21
DE60235576D1 (de) 2010-04-15
US20030180959A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
DE602004011931D1 (de) Gleichenden diagnose von alzheimer
ATE314354T1 (de) Radiopharmazeutika für die diagnose von alzheimer
DE60016178D1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
DK1420830T3 (da) Okular diagnose af Alzheimer-sygdom
NO992624D0 (no) Refleksalgoritme for tidlig og kostnadseffektiv diagnose av myokardialt infarkt som er egnede for atomatiserte diagnostiske innretninger
FI960268L (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
ATE336506T1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
DE60322848D1 (de) System für kontinuierliche leistungstests
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
DE60239377D1 (de) Träger für elektrophotographische Entwickler und Entwickler die den Träger enthalten
DE60235576D1 (de) Diagnostikum für die frühe phase von morbus alzheimer
EP1573440A4 (de) Verfahren zur diagnose von akathisie
EP1742654A4 (de) Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
DK0720745T3 (da) Fremgangsmåde til kvantificering af ekstracellulært BPI i legemsvæsker
RU2002110013A (ru) Способ диагностики скрытой эндотелиальной дисфункции у женщин
BR0110603A (pt) Couro natural revestido com poliuretano e método de preparação de couro natural revestido
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
PT1297342E (pt) Metodo de diagnostico para a doenca de alzheimer com base em holo-transcobalamina ii
PT1292187E (pt) Modelo animal transgenico de disturbios neurodegenerativos
FI951778A0 (fi) Menetelmä allergian toteamiseksi
FR3107371B1 (fr) Système de sélection d'une fragrance
ATE428932T1 (de) Diagnostische verwendung von scn2b für alzheimer erkrankung
EP1567045A4 (de) Verfahren zur diagnostizierung des vorliegens bzw. stadiums von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties